Psoriasis
Conditions
Brief summary
Psoriasis is a long standing inflammatory, autoinflammatory disease linked with many comorbidities. Patients with moderate to severe plaque psoriasis can be managed with topical as well as systemic medications. FDA approved Apremilast as first drug to be taken orally in cases of psoriasis in mid 1990's. Currently, according to researchers best knowledge no study has been done on use of Apremilast in Pakistan. It has recently become available here. Keeping in view all the benefits of this drug, a study has been planned to check its effectiveness and safety 30mg twice a day, in patients with moderate to severe chronic plaque psoriasis based on Psoriasis area and severity index and Body surface area assessments in our population.
Interventions
DRUGApremilast 30mg
Apremilast 30mg twice daily
Sponsors
Ghurki Trust and Teaching Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 59 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosed patients of chronic plaque psoriasis * patients applicant for oral or parenteral treatments and for light therapy * patients not responding to topical treatments
Exclusion criteria
* Patients who show hypersensitive reactions to apremilast to any of its inactive component * Pregnancy * Lactating mothers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Psoriasis area and severity index | 16 weeks |
| body surface area | 16 weeks |
Countries
Pakistan
Outcome results
None listed